| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
GPAT-IN-1 targets glycerol-3-phosphate acyltransferase (GPAT). GPAT is the first and rate-limiting enzyme in the synthesis of glycerolipids and triglycerides. It catalyzes the acylation of glycerol-3-phosphate to form lysophosphatidic acid, a key step in lipid biosynthesis. Inhibition of GPAT reduces triglyceride synthesis and may modulate lipid metabolism.
|
|---|---|
| ln Vitro |
GPAT-IN-1 (Compound 13b) suppresses GPAT with an IC50 value of 8.9 μM[1].
In vitro, GPAT-IN-1 (Compound 13b) inhibits GPAT with an IC50 of 8.9 μM. This demonstrates its potency as a GPAT inhibitor in biochemical assays. The compound can be used for research on obesity and diabetes, where modulation of lipid metabolism is a therapeutic target. |
| ln Vivo |
Specific in vivo activity data for GPAT-IN-1 are not extensively reported. As a GPAT inhibitor, it would be expected to modulate lipid metabolism in vivo. It may be utilized in obesity research to study the effects of reduced triglyceride synthesis on body weight and metabolic parameters.
|
| Enzyme Assay |
GPAT enzymatic activity is measured using biochemical assays with recombinant GPAT protein. The enzyme is incubated with glycerol-3-phosphate and acyl-CoA substrates in the presence of GPAT-IN-1 at varying concentrations. Product formation (lysophosphatidic acid) is measured, and IC50 values are calculated from dose-response curves.
|
| Cell Assay |
The cellular activity of GPAT-IN-1 is evaluated in cell lines. Cells are treated with the compound, and lipid synthesis or triglyceride levels are measured to assess GPAT inhibition. Radiolabeled fatty acid incorporation into triglycerides is commonly used to measure de novo lipogenesis.
|
| Animal Protocol |
In vivo efficacy of GPAT-IN-1 would typically be evaluated in animal models of obesity or diabetes. Animals would be administered the compound, and metabolic parameters such as body weight, lipid levels, and glucose homeostasis would be assessed. Hepatic triglyceride content would be measured as a pharmacodynamic endpoint.
|
| ADME/Pharmacokinetics |
GPAT-IN-1 has a molecular formula of C21H26ClNO4S and a molecular weight of 423.95 g/mol. The compound is stored under recommended conditions. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for GPAT-IN-1 are limited. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
GPAT-IN-1 is a glycerol-3-phosphate acyltransferase (GPAT) inhibitor with an IC50 of 8.9 μM. It can be used for research on obesity and diabetes. The compound is a valuable tool for studying lipid metabolism and the role of GPAT in metabolic disorders.
|
| Molecular Formula |
C21H26CLNO4S
|
|---|---|
| Molecular Weight |
423.953444004059
|
| Exact Mass |
423.13
|
| Elemental Analysis |
C, 59.50; H, 6.18; Cl, 8.36; N, 3.30; O, 15.10; S, 7.56
|
| CAS # |
1204347-51-2
|
| PubChem CID |
44608763
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
28
|
| Complexity |
577
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCS(=O)(=O)NC1=C(C=C(C=C1)C2=CC(=CC=C2)Cl)C(=O)O
|
| InChi Key |
AHHSQDHCFGYPOW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H26ClNO4S/c1-2-3-4-5-6-7-13-28(26,27)23-20-12-11-17(15-19(20)21(24)25)16-9-8-10-18(22)14-16/h8-12,14-15,23H,2-7,13H2,1H3,(H,24,25)
|
| Chemical Name |
3'-chloro-4-(octylsulfonamido)-[1,1'-biphenyl]-3-carboxylic acid
|
| Synonyms |
GPAT-IN-1; GPAT-IN 1; GPAT IN 1; GPAT
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3588 mL | 11.7938 mL | 23.5877 mL | |
| 5 mM | 0.4718 mL | 2.3588 mL | 4.7175 mL | |
| 10 mM | 0.2359 mL | 1.1794 mL | 2.3588 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
